Market revenue in 2021 | USD 144.4 million |
Market revenue in 2028 | USD 162.6 million |
Growth rate | 1.7% (CAGR from 2021 to 2028) |
Largest segment | Lucentis |
Fastest growing segment | Beouvu |
Historical data covered | 2017 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beouvu |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Lucentis was the largest segment with a revenue share of 50.48% in 2021. Horizon Databook has segmented the Middle East & Africa anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beouvu covering the revenue growth of each sub-segment from 2017 to 2028.
Considerable increase in prevalence of AMD in Africa, due to low living standards, unhealthy diet, and increasing geriatric population, has led to an increase in the need for novel & advanced treatments. Presence of major opportunities and improvements in healthcare facilities over the recent past in underdeveloped economies of the MEA are expected to fuel the region’s market.
The high cost of treatments is typically not affordable for the majority of the African population, due to a large number of people being below poverty line. Hence, an increase in demand for affordable substitutes, coupled with increasing penetration of generic products, is anticipated to drive the market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa anti-vascular endothelial growth factor therapeutics market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account